GDRX (GoodRx Holdings, Inc.) Stock Financials & Earnings

GDRXGoodRx Holdings, Inc.

Mkt Cap$829M

Revenue (TTM)$797M

Net Income (TTM)$83M

EPS (TTM)$0.09

Free Cash Flow (TTM)$108M

Gross Margin92.8%

Op. Margin11.0%

Net Margin10.4%

FCF Margin13.6%

P/S Ratio (TTM)1.0x

P/E Ratio (TTM)10.0x

YoY Rev Growth+0.6%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$184M	$167M	$11M
Q2 23	$190M	$173M	$18M
Q3 23	$180M	$161M	-$38M
Q4 23	$197M	$181M	-$18M
Q1 24	$198M	$185M	$7M
Q2 24	$201M	$189M	$20M
Q3 24	$195M	$184M	$20M
Q4 24	$199M	$186M	$18M
Q1 25	$203M	$190M	$23M
Q2 25	$203M	$170M	$28M
Q3 25	$196M	$183M	$15M
Q4 25	$195M	$197M	$22M

Revenue Breakdown

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q1 23	$33M	$30M	$79M
Q2 23	$31M	$27M	$80M
Q3 23	$40M	$35M	$92M
Q4 23	$32M	$30M	$94M
Q1 24	$31M	$41M	$90M
Q2 24	$31M	$28M	$93M
Q3 24	$30M	$26M	$90M
Q4 24	$32M	$24M	$94M
Q1 25	$31M	$30M	$85M
Q2 25	$30M	$28M	$85M
Q3 25	$31M	$32M	$84M
Q4 25	$29M	$24M	$79M

Revenue Segments

Quarter	Other Revenue	Pharma Manufacturer Solutions Revenues	Prescription Transactions Revenue	Subscription Revenue
Q1 23	$5M	$20M	$135M	$24M
Q2 23	$5M	$24M	$137M	$24M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$761M	$0	$761M
Q2 23	$762M	$0	$762M
Q3 23	$795M	$0	$795M
Q4 23	$672M	$0	$672M
Q1 24	$533M	$0	$533M
Q2 24	$525M	$0	$525M
Q3 24	$424M	$0	$424M
Q4 24	$448M	$0	$448M
Q1 25	$301M	$0	$301M
Q2 25	$281M	$0	$281M
Q3 25	$274M	$0	$274M
Q4 25	$262M	$0	$262M

Shares Outstanding

Revenue Per Employee

Revenue / Employee